

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

INSIDE INFORMATION
PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the parent of not more than approximately HK\$65 million for the six months ended 30 September 2022 as compared with a profit attributable to owners of the parent for the six months ended 30 September 2021 of approximately HK\$14.1 million.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*) (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**” or the “**Directors**”) of the Company would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the parent of not more than approximately HK\$65 million for the six months ended 30 September 2022 as compared with a profit attributable to owners of the parent for the six months ended 30 September 2021 of approximately HK\$14.1 million.

Such expected loss is mainly attributable to the combined effect of (i) decrease in fair value gains on investment properties; (ii) impairment losses on property, plant and equipment recorded for the six months ended 30 September 2022, against the reversal of impairment losses on property, plant and equipment recorded for the six months ended 30 September 2021; (iii) increase in fair value losses and impairment losses on financial assets; and (iv) decrease in revenue from property sales in agricultural produce exchange markets in the People’s Republic of China (through the Company’s listed subsidiary, China Agri-Products Exchange Limited) as compared to that for the corresponding period in 2021.

As the Company is still in the course of finalising its results for the six months ended 30 September 2022, the information contained in this announcement is solely based on the preliminary assessment by the Board after reviewing the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 which have yet to be finalised. Details of the performance of the Company for the six months ended 30 September 2022 will be disclosed in the interim results announcement of the Company, which is expected to be published on or before end of November 2022 in accordance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Tang Ching Ho
Chairman and Managing Director

Hong Kong, 11 November 2022

As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita, and the independent non-executive directors of the Company are Mr. Leung Wai Ho, Mr. Siu Man Ho, Simon, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.

* For identification purpose only